Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations
The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome co...
Read moreResearch & Access Updates
Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on deve...
Read moreTriplet Regimens Dominate the Relapsed/Refectory Myeloma Treatment Landscape
Novel triplet combinations are leading the key developments made in the treatment of patients with relaps...
Read moreJanssen files Darzalex Faspro for rare disease light chain amyloidosis
Janssen has filed a new formulation of its Darzalex in the US for the rare and potentially fatal disease...
Read moreSpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
SpringWorks Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing life-chan...
Read morePomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM):
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior e...
Read more